Boosting antibody therapy with complement

Boross, Péter; Leusen, Jeanette H.W.

doi:10.1182/blood-2012-04-420760

Cited by 14 publications

(19 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The same approach was further evaluated in a syngeneic model using the murine CR2 sequence coupled to the murine IgG2a Fc. 118,119 In vitro data were comparable with results obtained with the human fusion protein. Co-administration with anti-tumor mAbs led to an improved anti-tumor response in two syngeneic mouse models (metastatic EL4 T cell lymphoma and melanoma B16), with CDC playing a key role as effector mechanism.…”

Section: Inhibition Of Complement Regulatorssupporting

confidence: 77%

Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer

Meyer

Leusen

Boross

2014

mAbs

Self Cite

View full text Add to dashboard Cite

Section: Inhibition Of Complement Regulatorssupporting

confidence: 77%

Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer

Meyer

Leusen

Boross

2014

mAbs

Self Cite

View full text Add to dashboard Cite

“…Further studies are required to provide insights into its role in innate immunity. In general, Ag-specific Abs elicit immune defense through the activation of the classical complement system (20)(21)(22), pathogen neutralization (23,24), phagocytosis of apoptotic cells (25)(26)(27), and priming of immune cells (28,29).…”

Section: Igdmentioning

confidence: 99%

Natural Antibodies Bridge Innate and Adaptive Immunity

Panda

Ding

2015

The Journal of Immunology

273

259

View full text Add to dashboard Cite

Natural Abs, belonging to isotypes IgM, IgG3, and IgA, were discovered nearly half a century ago. Despite knowledge about the role of the polyreactive natural IgM in pathogen elimination, B cell survival and homeostasis, inflammatory diseases, and autoimmunity, there is a lack of clarity about the physiological role of natural IgG and natural IgA because they appear incapable of recognizing Ags on their own and are perceived as nonreactive. However, recent research revealed exciting functions of natural IgG in innate immunity. Natural IgG:lectin collaboration swiftly and effectively kills invading pathogens. These advances prompt further examination of natural Abs in immune defense and homeostasis, with the potential for developing novel therapeutics. This review provides new insights into the interaction between natural Abs and lectins, with implications on how interactions between molecules of the innate and adaptive immune systems bridge these two arms of immunity.

show abstract

“…The efficiency of CDC is dependent on many factors ‐ including target antigen density and antibody isotype (Bindon et al , ; Michaelsen et al , ; Dechant et al , ). Since CDC is considered as a relevant effector mechanism for class I antibodies (Glennie et al , ; Boross & Leusen, ), we wondered whether the CDC activity of rituximab could be improved. The current study demonstrated that at low CD20 antigen densities, especially in the case of CLL cells, a human IgG3 version of rituximab (C2B8‐IgG3) is more effective in triggering CDC than the approved IgG1 antibody (C2B8‐IgG1).…”

mentioning

confidence: 99%